Iron Oxide Nanoparticle Formulations for Supplementation.

Area of Science:

• Nanomedicine
• Biochemistry
• Pharmacology

Background:

• Intravenous (IV) iron formulations are nanoparticle iron-oxyhydroxide cores coated with carbohydrates.
• Clinical use began before nanomedicine exploration, leading to limited studies on iron release and biodistribution.
• These complex drugs pose challenges for bioequivalence evaluation.

Purpose of the Study:

• To investigate the pathogenesis of oxidative stress induced by IV iron formulations.
• To explore the relationship between carbohydrate shell characteristics and labile iron release.
• To highlight the need for comprehensive studies on IV iron safety, efficacy, and dosing.

Main Methods:

• Review of existing literature on IV iron formulations, nanoparticle characteristics, and oxidative stress mechanisms.
• Analysis of hypotheses regarding labile iron release and Fenton/Haber-Weiss reactions.
• Discussion of limitations in current pharmacokinetic analyses and bioequivalence studies.

Main Results:

• IV iron formulations are nanoparticles (5-100 nm) with iron-oxyhydroxide cores and carbohydrate shells.
• Smaller carbohydrate shells are associated with increased lability and direct plasma iron release.
• Labile iron can induce oxidative stress, targeting endothelial cells, myocardium, liver, and plasma proteins.

Conclusions:

• Oxidative stress from IV iron is hypothesized to stem from labile iron release, promoting free radical formation.
• Formulations with smaller carbohydrate shells may pose a higher risk of oxidative stress.
• Further research is needed on optimal dosing, long-term safety, and comparative efficacy of IV iron agents.